Journey Medical Corporation

Company Description

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Analysis

ANALYSIS: With an Obermatt 360° View of 14 (better than 14% compared with alternatives), overall professional sentiment and financial characteristics for the stock Journey Medical Corporation are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Journey Medical Corporation. The consolidated Growth Rank has a good rank of 99, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 99% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 18 means that the share price of Journey Medical Corporation is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 82% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 11, which means that the company has a riskier financing structure than 89% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 26, indicating professional investors are more pessimistic about the stock than for 74% of alternative investment opportunities. ...read more

Country

USA

Industry Pharmaceuticals

Size X-Small

Website journeymedicalcorp.com

Index

NASDAQ

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.